<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055180</url>
  </required_header>
  <id_info>
    <org_study_id>HFpEF-PHT 1.1</org_study_id>
    <nct_id>NCT05055180</nct_id>
  </id_info>
  <brief_title>Right Ventricular Function and Pulmonary Hypertension in HFpEF</brief_title>
  <acronym>HFpEF-PHT</acronym>
  <official_title>Afterload Dependence of Right Ventricular Myocardial Remodeling and Intrinsic Right Ventricular Myocardial Function in Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart Center Leipzig - University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heart Center Leipzig - University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with heart failure and preserved ejection fraction (HFpEF) right ventricular (RV)&#xD;
      systolic and diastolic dysfunction are prognostically and functionally relevant factors but&#xD;
      have mechanistically been neglected so far. In the present study alterations of intrinsic RV&#xD;
      (systolic and diastolic) function, as assessed by invasive pressure volume loops, are&#xD;
      examined in relation to tissue alterations on myocardial level and to the degree of RV&#xD;
      afterload (pulmonary hypertension). Study aim is to gain insights into mechanisms&#xD;
      contributing to the development of RV dysfunction and potentially identify new therapeutic&#xD;
      targets.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Right ventricular systolic and diastolic function</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessed with pressure volume loops analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biventricular myocardial fibrosis</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessed with histopathology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phosphorylation of structural myocardial proteins</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessed on myocardial biopsy specimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional capacity</measure>
    <time_frame>Baseline</time_frame>
    <description>6-Minute Walk Test / Spiroergometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial fibrosis on cardiac magnetic resonance</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>HFpEF with pulmonary hypertension</arm_group_label>
    <description>Invasively diagnosed HFpEF and pulmonary hypertension according to current guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFpEF without pulmonary hypertension</arm_group_label>
    <description>Invasively diagnosed HFpEF without pulmonary hypertension according to current guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without HFpEF</arm_group_label>
    <description>Patients without invasive evidence of HFpEF</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Invasive hemodynamics and myocardial biopsies</intervention_name>
    <description>Invasive hemodynamic characterization (biventricular pressure volume loop assessment) and biventricular myocardial biopsies</description>
    <arm_group_label>HFpEF with pulmonary hypertension</arm_group_label>
    <arm_group_label>HFpEF without pulmonary hypertension</arm_group_label>
    <arm_group_label>Patients without HFpEF</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biventricular myocardial tissue samples. Peripheral blood samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        outpatient general cardiology clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        HFpEF&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical signs of heart failure&#xD;
&#xD;
          -  Preserved Left ventricular (LV) Ejection Fraction (EF &gt;= 50%)&#xD;
&#xD;
          -  Structural Heart Diseases on echocardiogram/ N terminal-pro-brain natriuretic peptide&#xD;
             &gt; 125ng/l&#xD;
&#xD;
          -  Elevated LV end-diastolic pressure at rest (&gt;15mmHg) or during exertion (&gt;=25mmHg)&#xD;
&#xD;
        No Heart Failure&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  No signs of heart failure&#xD;
&#xD;
          -  Preserved Left ventricular (LV) Ejection Fraction (EF &gt;= 50%)&#xD;
&#xD;
          -  Normal LV end-diastolic pressure at rest (=&lt;15mmHg) and during exertion (&lt;25mmHg)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant coronary artery stenosis at time of catheterization&#xD;
&#xD;
          -  Acute coronary syndrome or cerebral insult within 1 month of examination&#xD;
&#xD;
          -  more than moderate valvular diseases&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  contraindication to cardiac magnetic resonance imaging&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Heart Center Leipzig at Leipzig University</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Lurz, MD, PhD</last_name>
      <phone>+49341865252022</phone>
      <email>Philipp.Lurz@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Karl-Philpp Rommel, MD</last_name>
      <phone>+49341865252529</phone>
      <email>Karl-Philip.Rommel@medizin.uni-leipzig.de</email>
    </contact_backup>
    <investigator>
      <last_name>Philipp Lurz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Besler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karl-Patrik Kresoja, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Rommel KP, von Roeder M, Oberueck C, Latuscynski K, Besler C, Blazek S, Stiermaier T, Fengler K, Adams V, Sandri M, Linke A, Schuler G, Thiele H, Lurz P. Load-Independent Systolic and Diastolic Right Ventricular Function in Heart Failure With Preserved Ejection Fraction as Assessed by Resting and Handgrip Exercise Pressure-Volume Loops. Circ Heart Fail. 2018 Feb;11(2):e004121. doi: 10.1161/CIRCHEARTFAILURE.117.004121.</citation>
    <PMID>29449367</PMID>
  </results_reference>
  <results_reference>
    <citation>von Roeder M, Kowallick JT, Rommel KP, Blazek S, Besler C, Fengler K, Lotz J, Hasenfuß G, Lücke C, Gutberlet M, Thiele H, Schuster A, Lurz P. Right atrial-right ventricular coupling in heart failure with preserved ejection fraction. Clin Res Cardiol. 2020 Jan;109(1):54-66. doi: 10.1007/s00392-019-01484-0. Epub 2019 May 3.</citation>
    <PMID>31053957</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

